Therma Bright Reviews Manufacturing Strategy in Light of US Tariff Changes
Therma Bright (TBRIF) is evaluating its manufacturing strategy for Venowave products in response to recent US tariff changes on Chinese-manufactured goods. The company is conducting a comprehensive review of manufacturing options including: complete onshoring to North America (Canada, USA, or Mexico), maintaining Chinese production with tariff mitigation strategies, or implementing a hybrid approach combining both locations.
The decision-making process considers multiple factors beyond costs, including:
- Supply chain resilience
- Production lead times
- Quality control measures
- Intellectual property protection
- Logistics efficiency
- Market access and geopolitical stability
The company continues to work with national distributors to expand Venowave's market presence. The Venowave VW5, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is an FDA-designated Durable Medical Equipment device that enhances vascular and lymphatic flow in lower limbs.
Therma Bright (TBRIF) sta valutando la sua strategia produttiva per i prodotti Venowave in risposta alle recenti modifiche dei dazi statunitensi sui beni prodotti in Cina. L'azienda sta conducendo una revisione approfondita delle opzioni di produzione che includono: la completa delocalizzazione in Nord America (Canada, USA o Messico), il mantenimento della produzione cinese con strategie di mitigazione dei dazi, oppure un approccio ibrido che combini entrambe le sedi.
Il processo decisionale prende in considerazione molteplici fattori oltre ai costi, tra cui:
- Resilienza della catena di approvvigionamento
- Tempi di produzione
- Controllo qualit脿
- Protezione della propriet脿 intellettuale
- Efficienza logistica
- Accesso al mercato e stabilit脿 geopolitica
L鈥檃zienda continua a collaborare con distributori nazionali per espandere la presenza di Venowave sul mercato. Il Venowave VW5, che rientra nei rimborsi Medicare e Medicaid sotto il codice HCPCS per 10 indicazioni mediche, 猫 un dispositivo medico durevole approvato dalla FDA che migliora il flusso vascolare e linfatico degli arti inferiori.
Therma Bright (TBRIF) est谩 evaluando su estrategia de fabricaci贸n para los productos Venowave en respuesta a los recientes cambios en los aranceles de EE.UU. sobre productos fabricados en China. La compa帽铆a est谩 realizando una revisi贸n exhaustiva de las opciones de producci贸n que incluyen: traslado completo a Norteam茅rica (Canad谩, EE.UU. o M茅xico), mantener la producci贸n en China con estrategias para mitigar los aranceles, o implementar un enfoque h铆brido que combine ambas ubicaciones.
El proceso de toma de decisiones considera m煤ltiples factores m谩s all谩 de los costos, tales como:
- Resiliencia de la cadena de suministro
- Tiempos de producci贸n
- Medidas de control de calidad
- Protecci贸n de la propiedad intelectual
- Eficiencia log铆stica
- Acceso al mercado y estabilidad geopol铆tica
La empresa contin煤a trabajando con distribuidores nacionales para expandir la presencia de Venowave en el mercado. El Venowave VW5, que califica para el reembolso bajo los c贸digos HCPCS de Medicare y Medicaid para 10 indicaciones m茅dicas, es un dispositivo m茅dico duradero aprobado por la FDA que mejora el flujo vascular y linf谩tico en las extremidades inferiores.
Therma Bright (TBRIF)電� 斓滉芳 氙戈淡鞚� 欷戧淡靷� 鞝滍拡鞐� 雽�頃� 甏�靹� 氤�瓴届棎 雽�鞚戫晿鞐� Venowave 鞝滍拡鞚� 鞝滌“ 鞝勲灥鞚� 韽夑皜頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 鞝滌“ 鞓奠厴鞚� 膦呿暕鞝侅溂搿� 瓴�韱� 欷戩澊氅�, 鞐赴鞐愲姅 攵侂(旌愲倶雼�, 氙戈淡, 氅曥嫓旖�)搿滌潣 鞕勳爠 鞚挫爠, 甏�靹� 鞕勴檾 鞝勲灥鞚� 鞝侅毄頃� 欷戧淡 靸濎偘 鞙犾, 霕愲姅 霊� 歆�鞐潉 瓴绊暕頃� 頃橃澊敫岆Μ霌� 氚╈晥鞚� 韽暔霅╇媹雼�.
鞚橃偓瓴办爼 瓿检爼鞐愳劀電� 牍勳毄 鞕胳棎霃� 雼れ潓瓿� 臧欖潃 鞐煬 鞖旍唽毳� 瓿犽牑頃╇媹雼�:
- 瓿店笁毵� 須岆车霠�
- 靸濎偘 毽摐韮�鞛�
- 頀堨 甏�毽�
- 歆�鞁� 鞛偘甓� 氤错樃
- 氍茧 須湪靹�
- 鞁滌灔 鞝戧芳靹标臣 歆�鞝曧暀鞝� 鞎堨爼靹�
須岇偓電� Venowave鞚� 鞁滌灔 鞝愳湢鞙� 頇曤寑毳� 鞙勴暣 甑偞 鞙犿喌鞐呾泊鞕� 瓿勳啀 順戨牓頃橁碃 鞛堨姷雼堧嫟. Venowave VW5電� 10臧�歆� 鞚橂 鞝侅潙歃濎棎 雽�頃� 氅旊敂旒�鞏� 氚� 氅旊敂旒�鞚措摐 HCPCS 旖旊摐 頇橁笁 鞛愱博鞚� 鞛堨溂氅�, FDA 歆�鞝� 雮搓惮靹� 鞚橂旮瓣赴搿� 頃橃泊鞚� 順堦磤 氚� 毽柬攧 頋愲鞚� 臧滌劆頃╇媹雼�.
Therma Bright (TBRIF) 茅value sa strat茅gie de fabrication des produits Venowave en r茅ponse aux r茅cents changements tarifaires am茅ricains sur les produits fabriqu茅s en Chine. L鈥檈ntreprise m猫ne une revue compl猫te des options de production incluant : une relocalisation totale en Am茅rique du Nord (Canada, 脡tats-Unis ou Mexique), le maintien de la production en Chine avec des strat茅gies d鈥檃tt茅nuation des droits de douane, ou une approche hybride combinant les deux sites.
Le processus d茅cisionnel prend en compte plusieurs facteurs au-del脿 des co没ts, notamment :
- R茅silience de la cha卯ne d鈥檃pprovisionnement
- D茅lais de production
- Mesures de contr么le qualit茅
- Protection de la propri茅t茅 intellectuelle
- Efficacit茅 logistique
- Acc猫s au march茅 et stabilit茅 g茅opolitique
L鈥檈ntreprise continue de collaborer avec des distributeurs nationaux pour 茅tendre la pr茅sence de Venowave sur le march茅. Le Venowave VW5, 茅ligible au remboursement Medicare et Medicaid sous le code HCPCS pour 10 indications m茅dicales, est un dispositif m茅dical durable approuv茅 par la FDA qui am茅liore le flux vasculaire et lymphatique des membres inf茅rieurs.
Therma Bright (TBRIF) bewertet seine Fertigungsstrategie f眉r Venowave-Produkte als Reaktion auf die j眉ngsten US-Zoll盲nderungen f眉r in China hergestellte Waren. Das Unternehmen f眉hrt eine umfassende 脺berpr眉fung der Fertigungsoptionen durch, darunter: vollst盲ndige Verlagerung nach Nordamerika (Kanada, USA oder Mexiko), Beibehaltung der chinesischen Produktion mit Zollminderungsstrategien oder die Umsetzung eines hybriden Ansatzes, der beide Standorte kombiniert.
Der Entscheidungsprozess ber眉cksichtigt mehrere Faktoren 眉ber die Kosten hinaus, darunter:
- Resilienz der Lieferkette
- Produktionsdurchlaufzeiten
- 蚕耻补濒颈迟盲迟蝉办辞苍迟谤辞濒濒尘补脽苍补丑尘别苍
- Schutz des geistigen Eigentums
- Logistische Effizienz
- Zugang zum Markt und geopolitische Stabilit盲t
Das Unternehmen arbeitet weiterhin mit nationalen Vertriebspartnern zusammen, um die Marktpr盲senz von Venowave auszubauen. Das Venowave VW5, das f眉r die Erstattung durch Medicare und Medicaid unter dem HCPCS-Code f眉r 10 medizinische Indikationen qualifiziert ist, ist ein von der FDA zugelassenes dauerhaftes medizinisches Ger盲t, das den vaskul盲ren und lymphatischen Fluss in den unteren Gliedma脽en verbessert.
- Venowave VW5 qualifies for Medicare and Medicaid reimbursement
- Company expanding market presence through national distributors
- Multiple manufacturing options under evaluation to optimize costs
- US tariffs may significantly increase product costs
- Manufacturing uncertainty could impact supply chain stability
- Potential increased operational costs regardless of chosen manufacturing strategy
Toronto, Ontario--(Newsfile Corp. - April 16, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update to address the potential impact of recent and evolving US tariff policies on our current manufacturing operations of Venowave in China, which serves the US market.
The Company is actively reviewing the implications of recent tariff changes imposed by the US on goods manufactured in foreign countries, particularly China. These tariffs have the potential to significantly increase the cost of our products sold in the US market. In response, Therma has initiated a comprehensive review of all available manufacturing options to ensure the long-term competitiveness and stability of our supply chain.
Therma is reviewing various manufacturing options which includes a thorough analysis of onshoring and establishing manufacturing capabilities within North America (Canada, USA, or Mexico).
The Company is also considering a hybrid approach; combining manufacturing of Venowave or component parts in China with onshoring in North America. In the case of continued full manufacturing of Venowave in China the option will be evaluated in conjunction with strategies to mitigate tariff costs, including potential absorption of some or all tariff expenses if financially feasible in the current dynamic environment.
The Company's decision-making process will extend beyond pure cost considerations and will encompass critical factors such as:
- Supply chain resilience: assessing the stability and reliability of different manufacturing locations and potential risks.
- Lead Times: evaluating the impact on production and delivery timelines.
- Quality Control: ensuring consistent product quality across different manufacturing environments.
- Intellectual Property Protection: considering the risks associated with different manufacturing locations.
- Logistics and Transportation: analysing the efficiency and cost of moving goods from various manufacturing sites to the US market.
- Market Access and Geopolitical Stability: evaluating the long-term implications of manufacturing locations on market access and geopolitical risks.
Therma Bright recognizes that the current tariff landscape is subject to change. Our analysis will consider various potential scenarios and their impact on our business.
It is important to emphasize that no final decision regarding our future manufacturing strategy has been made at this time. The Company is committed to keeping our shareholders informed. We will provide a further update once our comprehensive review is complete and a definitive course of action has been determined. We appreciate our shareholders' understanding as we navigate this evolving situation and work to ensure the long-term success of the Company.
Therma Bright would also like to announce that it continues to work with national distributors to expand the market presence for Venowave with further updates in the near future.
The Venowave VW5, which qualifies for Medicare and Medicaid HCPCS code reimbursement under 10 medical indications, is a compact, battery-operated peristaltic pump designed to enhance vascular and lymphatic flow in the lower limbs. When strapped below the knee, the device generates a wave-form motion that compresses the calf, promoting upward displacement of venous and lymphatic fluid. Powered by a single rechargeable 1.5V NiMH AA battery, the FDA-designated Durable Medical Equipment (DME) device allows users to receive treatment while staying active. The Venowave VW5 is built for durability and supports repeated use across multiple patients.
About Therma Bright Inc.
Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.
Rob Fia, CEO
[email protected]
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as manufacturing and future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit
FAQ
How will US tariff changes impact Therma Bright's (TBRIF) Venowave manufacturing costs?
What manufacturing alternatives is TBRIF considering for Venowave production?
What medical reimbursements are available for the Venowave VW5 device?
What are the key factors TBRIF is considering in its manufacturing decision?
